ReviewAIDS research and treatment2016
The Need for Pediatric Formulations to Treat Children with HIV.
Review in AIDS research and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Characterizing the HIV care continuum among children and adolescents with HIV in eastern and southern Africa in the era of "Universal Test and Treat": A systematic review and meta-analysis.Journal of the International AIDS Society · 2025Pooled it
- Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.The New England journal of medicine · 2025Trial
- A Randomized Trial of Point-of-Care Early Infant Human Immunodeficiency Virus (HIV) Diagnosis in Zambia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to < 18 Years.Drug safety · 2021Trial
- Trial
- Trial
- Proof-of-Concept Development and Preclinical Evaluation of a Microarray Patch Platform for Codelivery of Multiple Broadly Neutralizing Antibodies for HIV Prevention.Molecular pharmaceutics · 2026Article
- Challenges with drug management of children and adolescents living with human immunodeficiency virus on antiretroviral therapy: A narrative review.African journal of primary health care & family medicine · 2026Review
- Harnessing Pharmacokinetic Modeling to Develop a Long-Acting Subcutaneous HIV Treatment Platform for Young Children.Pharmaceutics · 2026Article
- Clinical and immunovirological status in children, adolescents and young adults with early-life-acquired HIV: a Spanish multi-cohort analysis since 2020.The Journal of antimicrobial chemotherapy · 2026Article
- Design of SLS 3D-printed pediatric combination printlets of lamivudine and tenofovir disoproxil fumarate by understanding the impact of formulation and process variables on flow, spectral, thermal and performance characteristics.International journal of pharmaceutics · 2025Article
- HIV drug resistance in children and adolescents on NNRTI-based antiretroviral therapy and subsequent virologic response to dolutegravir-based regimens in Ghana.AIDS research and therapy · 2025Article
- Barriers to viral suppression in children aged 9 years or younger on dolutegravir-based antiretroviral therapy in Malawi, a mixed-methods study.PLOS global public health · 2025Article
- The Impact of the Core-Shell Fiber Composition on the Properties and Stability of the Electrospun Films.Nanotechnology, science and applications · 2025Article
- Article
- Considerable variation in the 95-95-95 targets accomplishment between children and adults might delay achievement of set targets.Frontiers in public health · 2025Review
- South African Parents' and Grandparents' Perspectives on the Acceptability of Implant Delivery of Treatment to Young Children with HIV.AIDS and behavior · 2025Article
- Follow-up for 3 years of a pediatric population diagnosed in 2018 with mother-to-child transmission of HIV in 8 Latin American countries in the PLANTAIDS cohort.BMC infectious diseases · 2024Article
- Challenges with pediatric antiretroviral therapy administration: Qualitative perspectives from caregivers and HIV providers in Kenya.PloS one · 2024Article
- Microencapsulation Techniques in HIV Pediatric Formulations: Advances and Future Outlook.Advances in pharmacological and pharmaceutical sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
Over 3.2 million children worldwide are infected with HIV, but only 24% of these children receive antiretroviral therapy (ART). ART adherence among children is a crucial part of managing human-immunodeficiency virus (HIV) infection and extending the life and health of infected children. Important causes of poor adherence are formulation- and regimen-specific properties, including poor palatability, large pill burden, short dosing intervals, and the complex storage and transportation of drugs. This review aims to summarize the various regimen- and formulation-based barriers to ART adherence among children to support the need for new and innovative pediatric formulations for antiretroviral therapy (ART). Detailing the arguments both for and against investing in the development of pediatric HIV medications, as well as highlighting recent advances in pediatric ART formulation research, provides a synopsis of the current data related to pediatric ART formulations and adherence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.